Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENETIC-AF
NL-OMON43294Phase 2Active, not recruiting
- Sponsor
- Oruka Therapeutics
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib), atrial flutter (AFL) and heart failure with reduced ejection fraction (HFrEF) comparing Bucindolol with Toprol-XL (2 arms). Primary endpoint: Time to first event of symptomatic AF/AFL or all-cause mortality. Started Nov 2016; status: active, not recruiting.
02
Drugs
bucindololmetoprolol
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON43294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43294.